市場調査レポート
商品コード
1318829

EVベースのリキッドバイオプシーの世界市場 (2023-2032年):提供区分・ワークフロー・サンプルタイプ・エンドユーザー・技術・地域別の分析・予測・競合情勢

Global EV-Based Liquid Biopsy Market - A Global and Regional Analysis: Focus on Offering, Workflow, Sample Type, End User, Technology, Regional Analysis, and Competitive Landscape - Analysis and Forecast, 2023-2032

出版日: | 発行: BIS Research | ページ情報: 英文 166 Pages | 納期: 1~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
EVベースのリキッドバイオプシーの世界市場 (2023-2032年):提供区分・ワークフロー・サンプルタイプ・エンドユーザー・技術・地域別の分析・予測・競合情勢
出版日: 2023年07月21日
発行: BIS Research
ページ情報: 英文 166 Pages
納期: 1~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

EVベースリキッドバイオプシー:世界市場の概要

世界のEVベースリキッドバイオプシーの市場規模は、2022年の7,822万米ドルから、予測期間中は19.73%のCAGRで推移し、2032年には4億5,553万米ドルに達すると予測されています。

同市場の成長は、継続的な技術の進歩、ヘルスケアプロバイダーによる採用の増加、個別化医療への注目の高まりによって牽引されると予測されています。

主要市場統計
開始年 2023年
予測年 2032年
開始年の市場規模 9,009万米ドル (2023年)
市場規模予測 4億5,553万米ドル (2032年)
CAGR (%) 19.73%

市場のライフサイクルステージ

世界のEVベースリキッドバイオプシーの市場は、学術研究の増加や市場での製品の承認により、発展中の段階にあります。さらに、個別化医療とプレシジョンオンコロジーにおけるEVベースリキッドバイオプシーの用途の拡大も市場のさらなる拡大を促進すると予測されています。

提供区分別では、キット・アッセイの部門が2022年の市場を独占しています。分離キット、アッセイ、付属品の採用が増加しており、同部門の成長に寄与しています。さまざまなエクソソームやEV分離キットが各種処置やリキッドバイオプシー検査の実施で使用されています。

技術別では、分離の部門が2022年の市場を独占しています。分離技術では、沈殿がもっとも一般的に使用される技術として浮上しています。ワークフロー別では、サンプル調製の部門が2022年の市場をリードしました。また、エンドユーザー別では、学術・研究機関の部門が同年の市場で最大のシェアを示しました。これらの機関は主に、バイオマーカーの同定、医薬品開発、標的取得のための細胞分析を目的とした研究活動に従事しています。

地域別では、北米地域が2022年の市場を独占し、予測期間を通じてその優位性を維持すると予想されています。一方で、いくつかの新興国を擁するアジア太平洋地域は予測期間中、21.64%のCAGRで最大の成長率を記録すると予測されています。

主要企業プロファイル

  • Abcam plc
  • Bio-Techne Corporation
  • Horiba Ltd.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Malvern Panalytical Ltd
  • Lonza Group AG
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Takara Bio Inc.
  • Norgen Biotek Corp.

当レポートでは、世界のEVベースリキッドバイオプシーの市場を調査し、市場の定義と概要、EV分離・分析の手法、法規制・償還環境、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 定義

第2章 調査範囲

第3章 調査手法

第4章 市場概要

第5章 EVの分離・分析の手法

  • 概要
  • 分離手法
  • 分析手法

第6章 産業考察

  • 概要
  • 米国の法的要件
  • 欧州の法的要件と枠組み
  • アジア太平洋における法的要件と枠組み
  • 償還シナリオ

第7章 市場力学

  • 概要
  • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第8章 競合情勢

  • 競合情勢の概要
  • 市場シェア分析
  • 成長シェア分析

第9章 世界のEVベースリキッドバイオプシー市場:提供区分別

  • キット・アッセイ
  • サービス
  • 機器

第10章 世界のEVベースリキッドバイオプシー市場:ワークフロー別

  • サンプル調製
  • シーケンス
  • データ分析

第11章 世界のEVベースリキッドバイオプシー市場:技術別

  • 絶縁技術
    • 沈殿
    • 超遠心分離
    • クロマトグラフィー
  • 分析技術
    • NGS
    • PCR
    • フローサイトメトリー

第12章 世界のEVベースリキッドバイオプシー市場:サンプルタイプ別

  • 尿
  • 唾液
  • その他

第13章 世界のEVベースリキッドバイオプシー市場:エンドユーザー別

  • 学術研究機関
  • 製薬会社・バイオテクノロジー会社
  • 臨床検査ラボ

第14章 世界のEVベースリキッドバイオプシー市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東
  • その他の地域

第15章 企業プロファイル

  • 企業概要
図表

List of Figures

  • Figure 1: Global EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
  • Figure 2: Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
  • Figure 3: Global EV-Based Liquid Biopsy Market (by Region), 2022
  • Figure 4: Global EV-Based Liquid Biopsy Market Segmentation
  • Figure 5: Global EV-Based Liquid Biopsy Market Regional Segmentation
  • Figure 6: Global EV-Based Liquid Biopsy Market Methodology
  • Figure 7: Primary Research Methodology
  • Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 9: Top-Down Approach (Segment-Wise Analysis)
  • Figure 10: Global EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 11: Subtypes of Evs
  • Figure 12: Methods of EV-Isolation from Biofluids
  • Figure 13: Workflow of Differential Ultracentrifugation for Exosome Isolation
  • Figure 14: Methods of EV-Analysis
  • Figure 15: Global EV-Based Liquid Biopsy Market - Market Dynamics
  • Figure 16: Structure of Evs Enveloped by Protective Lipid Membrane
  • Figure 17: Number of Research Publications on Exosomes, 2015-2021
  • Figure 18: Share of New Cancer Cases, 2020
  • Figure 19: Number of Cancer Cases, 2020
  • Figure 20: Currently Investigated Circulating Biomarkers Associated with Evs
  • Figure 21: Share of Key Developments and Strategies, January 2019-June 2023
  • Figure 22: Share of Product Launch and Expansion Activities (by Company), January 2019-June 2023
  • Figure 23: Share of Synergistic Activities (by Company), January 2019-June 2023
  • Figure 24: Share of Other Activities (by Company), January 2019-June 2023
  • Figure 25: Market Share Analysis for Global EV-Based Liquid Biopsy Market, 2022
  • Figure 26: Growth-Share Analysis for Global EV-Based Liquid Biopsy Market (by Company), 2021-2022
  • Figure 27: Global EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
  • Figure 28: Global EV-Based Liquid Biopsy Market (Kits and Assays), $Million, 2022-2032
  • Figure 29: Global EV-Based Liquid Biopsy Market (Services), $Million, 2022-2032
  • Figure 30: Global EV-Based Liquid Biopsy Market (Instruments), $Million, 2022-2032
  • Figure 31: Global EV-Based Liquid Biopsy Market (by Workflow), $Million, 2022 and 2032
  • Figure 32: Global EV-Based Liquid Biopsy Market (Sample Preparation), $Million, 2022-2032
  • Figure 33: Global EV-Based Liquid Biopsy Market (Sequencing), $Million, 2022-2032
  • Figure 34: Global EV-Based Liquid Biopsy Market (Data Analysis), $Million, 2022-2032
  • Figure 35: Global EV-Based Liquid Biopsy Market (by Technology)
  • Figure 36: Global EV-Based Liquid Biopsy Market (by Technology), $Million, 2022 and 2032
  • Figure 37: Global EV-Based Liquid Biopsy Market (Isolation Technologies), $Million, 2022-2032
  • Figure 38: Global EV-Based Liquid Biopsy Market (Precipitation), $Million, 2022-2032
  • Figure 39: Global EV-Based Liquid Biopsy Market (Ultracentrifugation), $Million, 2022-2032
  • Figure 40: Global EV-Based Liquid Biopsy Market (Chromatography), $Million, 2022-2032
  • Figure 41: Global EV-Based Liquid Biopsy Market (Analysis Technologies), $Million, 2022-2032
  • Figure 42: Global EV-Based Liquid Biopsy Market (NGS), $Million, 2022-2032
  • Figure 43: Global EV-Based Liquid Biopsy Market (PCR), $Million, 2022-2032
  • Figure 44: Global EV-Based Liquid Biopsy Market (Flow Cytometry), $Million, 2022-2032
  • Figure 45: Global EV-Based Liquid Biopsy Market (by Sample Type)
  • Figure 46: Global EV-Liquid Biopsy Market (by Sample Type), $Million, 2022 and 2032
  • Figure 47: Global EV-Based Liquid Biopsy Market (Blood), $Million, 2022-2032
  • Figure 48: Global EV-Based Liquid Biopsy Market (Urine), $Million, 2022-2032
  • Figure 49: Global EV-Based Liquid Biopsy Market (Saliva), $Million, 2022-2032
  • Figure 50: Global EV-Based Liquid Biopsy Market (Other Biofluids), $Million, 2022-2032
  • Figure 51: Global EV-Based Liquid Biopsy Market (by End User)
  • Figure 52: Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
  • Figure 53: Global EV-Based Liquid Biopsy Market (Academic and Research Institutes), $Million, 2022-2032
  • Figure 54: Global EV-Based Liquid Biopsy Market (Pharmaceutical and Biotechnology Companies), $Million, 2022-2032
  • Figure 55: Global EV-Based Liquid Biopsy Market (Clinical Laboratories), $Million, 2022-2032
  • Figure 56: Global EV-Based Liquid Biopsy Market Snapshot (by Region)
  • Figure 57: Global EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
  • Figure 58: North America EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 59: North America: Market Dynamics
  • Figure 60: North America EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 61: U.S. EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 62: Canada EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 63: Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 64: Europe: Market Dynamics
  • Figure 65: Europe EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 66: Germany EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 67: U.K. EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 68: France EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 69: Italy EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 70: Spain EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 71: Rest-of-Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 72: Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 73: Asia-Pacific: Market Dynamics
  • Figure 74: Asia-Pacific EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 75: China EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 76: Japan EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 77: India EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 78: South Korea EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 79: Australia EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 80: Singapore EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 81: Rest-of-Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 82: Latin America and Middle East EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 83: Latin America and Middle East: Market Dynamics
  • Figure 84: Latin America and Middle East EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 85: Brazil EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 86: Mexico EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 87: Saudi Arabia EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 88: Rest-of-Latin America and Middle East EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 89: Rest-of-the-World EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 90: Total Number of Companies Profiled
  • Figure 91: Abcam plc: Product Portfolio
  • Figure 92: Bio-Techne Corporation: Product Portfolio
  • Figure 93: Horiba Ltd.: Product Portfolio
  • Figure 94: Qiagen N.V.: Product Portfolio
  • Figure 95: Thermo Fisher Scientific, Inc.: Product Portfolio
  • Figure 96: Malvern Panalytical Ltd: Product Portfolio
  • Figure 97: Lonza Group AG: Product Portfolio
  • Figure 98: Revvity, Inc. (PerkinElmer Inc.): Product Portfolio
  • Figure 99: Takara Bio Inc.: Product Portfolio
  • Figure 100: Norgen Biotek Corp.: Product Portfolio

List of Tables

  • Table 1: Current and Future State of EV-Based Liquid Biopsy in Industries
  • Table 2: Example of Few Commercial Kits Available for EV Isolation
  • Table 3: Advantages and Disadvantages of the EV Isolation Methods
  • Table 4: Emerging Methods for the Isolation of Exosomes
  • Table 5: Advantages and Disadvantages of Analysis Methods for Evs
  • Table 6: Legal Requirements in the U.S.
  • Table 7: Legal Landscape for EV-Based Liquid Biopsies in Europe
  • Table 8: Size and Densities of Evs and Various Lipoproteins
  • Table 9: Technological Advancements in EV-Based Liquid Biopsy
目次
Product Code: BHP1400SA

“Global EV-Based Liquid Biopsy Market to Reach $455.53 Million by 2032.”

Global EV-Based Liquid Biopsy Market Overview

The global EV-based liquid biopsy market was valued at $78.22 million in 2022 and is anticipated to reach $455.53 million by 2032, witnessing a CAGR of 19.73% during the forecast period 2023-2032. The global EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Start Year:2023
Forecast Year2032
Start Value$90.09 Million in 2023
Forecast Value$455.53 Million by 2032
CAGR %19.73%

Market Lifecycle Stage

The global EV-based liquid biopsy market is in progressing phase, which can be attributed to the increase in academic research and approval of products in the market. Furthermore, the expanding applications of EV-based liquid biopsy in personalized medicine and precision oncology are projected to drive further market expansion.

Impact

The adoption of EV-based liquid biopsy has revolutionized disease diagnosis and monitoring, offering numerous benefits over traditional biopsy methods. Its non-invasiveness, real-time monitoring capabilities, and potential for early disease detection have transformed the field of healthcare diagnostics. By providing a less invasive and more accessible method for detecting and monitoring diseases, particularly cancer, EV-based liquid biopsy has improved patient experiences, reduced healthcare costs, and enhanced overall healthcare outcomes. In addition, the entry of several established players, such as Thermo Fisher Scientific Inc., QIAGEN N.V., and Bio-Techne Corporation, is expected to aid the market growth.

Furthermore, the growth of the EV-based liquid biopsy market has stimulated research and development activities, fostered collaborations between industry players and academic institutions, and generated economic opportunities.

Market Segmentation:

Segmentation 1: by Offering

  • Kits and Assays
  • Services
  • Instruments

Kits and Assays Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Offering)

Based on offering, the kits and assays segment dominated the global EV-based liquid biopsy market in FY2022. The increasing adoption of isolation kits, assays, and accessories contributed to the prominence of this segment. Various exosome and EV isolation kits are being used to carry out several procedures and liquid biopsy tests.

Segmentation 2: by Technology

  • Isolation
  • Analysis

Isolation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Technology)

Based on technology, the isolation segment dominated the global EV-based liquid biopsy market in FY2022. Under isolation technology, precipitation emerged as the most common technology used.

Segmentation 3: by Workflow

  • Sample Preparation
  • Sequencing
  • Data Analysis

Sample Preparation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Workflow)

Based on workflow, the EV-based liquid biopsy market was dominated by the sample preparation segment in FY2022. The sample preparation or pre-analytical phase in the EV-based liquid biopsy workflow includes specimen collection, stabilization, transport, enrichment, processing, isolation, and quality assessment of the analyte.

Segmentation 4: by End User

  • Academic and Research Institutes
  • Clinical Laboratories
  • Pharmaceutical and Biotechnology Companies

Academic and Research Institutes Segment to Dominate the Global EV-Based Liquid Biopsy Market (by End User)

Based on end user, academic and research segment accounted for the largest share of the global EV-based liquid biopsy market in FY2022. Academic and research institutes play a vital role in the adoption of EV-based liquid biopsy methods, serving as essential facilities for both companies and independent academic research. These institutions are primarily engaged in research activities aimed at identifying biomarkers, developing drugs, and conducting cell analysis to acquire targets.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America and Middle East
  • Rest-of-the-World

In 2022, the North America region dominated the global EV-based liquid biopsy market, and it is expected to hold its dominance throughout the forecast period 2023-2032. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 21.64% in the market during the forecast period 2023-2032.

Demand - Drivers, Restraints, and Opportunities

Market Demand Drivers:

  • Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
  • Amplified Funding and Dedicated Research Efforts
  • Increasing Prevalence of Cancers

Market Restraints:

  • Lack of Standardized EV Isolation and Characterization Protocols
  • Lack of Precise EV Subtype Classification and Biomarkers Validation

Market Opportunities:

  • Advancements in EV-Based Liquid Biopsy Technologies
  • Development of New EV-Based Biomarkers
  • Approved Products in the Market

How can this report add value to an organization?

  • Workflow/Innovation Strategy: The EV-based liquid biopsy market (by offering) has been segmented into kits and assays, instruments, and services. Moreover, the study provides the reader with a detailed understanding of the different types of technologies, end-users, and sample types used in these tests.
  • Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of Evs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.
  • Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

EV-based liquid biopsy refers to the use of extracellular vesicles (Evs) as a non-invasive diagnostic tool for detecting and monitoring various diseases, including cancer. The global EV-based liquid biopsy market has experienced substantial growth driven by technological advancements, rising demand for non-invasive diagnostics, and the global increase in cancer prevalence.

Key Companies Profiled:

  • Abcam plc
  • Bio-Techne Corporation
  • Horiba Ltd.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Malvern Panalytical Ltd
  • Lonza Group AG
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Takara Bio Inc.
  • Norgen Biotek Corp.

Table of Contents

1 Definition

  • 1.1 Inclusion and Exclusion Criteria

2 Research Scope

  • 2.1 Target Audience
  • 2.2 Key Questions Answered in the Report:

3 Research Methodology

  • 3.1 Global EV-Based Liquid Biopsy Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Markets Overview

  • 4.1 Market Introduction
  • 4.2 Current and Future State of EV-Based Liquid Biopsy in Industries
  • 4.3 Current Market Size and Growth Potential, $Million, 2022-2032
  • 4.4 COVID-19 Impact on Global EV-based Liquid Biopsy Market
    • 4.4.1 Impact on Operations
    • 4.4.2 COVID-19 Impact: Current Scenario of the Market

5 Methods of EV Isolation and Analysis

  • 5.1 Overview
    • 5.1.1 Evs Introduction
  • 5.2 Isolation Methods
    • 5.2.1 EV Isolation Techniques Utilizing Ultracentrifugation Methods
      • 5.2.1.1 Differential Ultracentrifugation
      • 5.2.1.2 Density Gradient Centrifugation
      • 5.2.1.3 Moving Zone or Rate-Zonal Centrifugation
      • 5.2.1.4 Isopycnic Centrifugation
    • 5.2.2 EV Isolation Techniques Utilizing Size-Based Methods
      • 5.2.2.1 Ultrafiltration
      • 5.2.2.2 Sequential Filtration
      • 5.2.2.3 Size Exclusion Chromatography (SEC)
      • 5.2.2.4 Flow Field-Flow Fractionation (FFFF)
      • 5.2.2.5 Hydrostatic Filtration Dialysis (HFD)
    • 5.2.3 EV Isolation Techniques Utilizing Immunoaffinity Methods
      • 5.2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
      • 5.2.3.2 Magneto-Immunoprecipitation
    • 5.2.4 EV Isolation Techniques Utilizing Precipitation Methods
      • 5.2.4.1 Polyethylene Glycol (PEG) Precipitation
      • 5.2.4.2 Lectin Induced Agglutination
    • 5.2.5 EV Isolation Techniques Utilizing Microfluidic Technology
    • 5.2.6 EV Isolation Techniques Utilizing Commercial Kits
    • 5.2.7 Advantages and Disadvantages of the EV Isolation Methods
    • 5.2.8 Novel Approaches for Exosome Isolation
  • 5.3 Analysis Methods
    • 5.3.1 Advantages and Disadvantages of Analysis Methods for Evs

6 Industry Insights

  • 6.1 Overview
  • 6.2 Legal Requirements in the U.S.
  • 6.3 Legal Requirements and Frameworks in Europe
  • 6.4 Legal Requirements and Frameworks in Asia-Pacific
  • 6.5 Reimbursement Scenario

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Impact Analysis
  • 7.3 Market Drivers
    • 7.3.1 Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
    • 7.3.2 Amplified Funding and Dedicated Research Efforts
    • 7.3.3 Rising Prevalence of Cancers
  • 7.4 Market Restraints
    • 7.4.1 Lack of Standardized EV Isolation and Characterization Protocols
    • 7.4.2 Lack of Precise EV Subtype Classification and Biomarkers Validation
  • 7.5 Market Opportunities
    • 7.5.1 Advancements in EV-Based Liquid Biopsy Technologies
    • 7.5.2 Development of New EV-Based Biomarkers
    • 7.5.3 Approved Products in the Market

8 Competitive Landscape

  • 8.1 Competitive Landscape Overview
    • 8.1.1 Key Developments
    • 8.1.2 Product Launches and Expansion Activities
    • 8.1.3 Merger and Acquisition Activities
    • 8.1.4 Synergistic Activities
    • 8.1.5 License and Agreement Activities
    • 8.1.6 Other Activities
  • 8.2 Market Share Analysis (2022)
  • 8.3 Growth-Share Analysis (2021-2022)
    • 8.3.1 Growth-Share Analysis (by Company)

9 Global EV-Based Liquid Biopsy Market (by Offering),$Million, 2022-2032

  • 9.1 Overview
  • 9.2 Kits and Assays
  • 9.3 Services
  • 9.4 Instruments

10 Global EV-Based Liquid Biopsy Market (by Workflow), $Million, 2022-2032

  • 10.1 Overview
    • 10.1.1 Sample Preparation
    • 10.1.2 Sequencing
    • 10.1.3 Data Analysis

11 Global EV-Based Liquid Biopsy Market (by Technology), $Million, 2022-2032

  • 11.1 Overview
  • 11.2 Isolation Technologies
    • 11.2.1 Precipitation
    • 11.2.2 Ultracentrifugation
    • 11.2.3 Chromatography
  • 11.3 Analysis Technologies
    • 11.3.1 NGS
    • 11.3.2 PCR
    • 11.3.3 Flow Cytometry

12 Global EV-Based Liquid Biopsy Market (by Sample Type), $Million, 2022-2032

  • 12.1 Overview
    • 12.1.1 Blood
    • 12.1.2 Urine
    • 12.1.3 Saliva
    • 12.1.4 Other Biofluids

13 Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022-2032

  • 13.1 Overview
  • 13.2 Academic and Research Institutes
  • 13.3 Pharmaceutical and Biotechnology Companies
  • 13.4 Clinical Laboratories

14 Global EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032

  • 14.1 Overview
  • 14.2 North America
    • 14.2.1 U.S.
    • 14.2.2 Canada
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 U.K.
    • 14.3.3 France
    • 14.3.4 Italy
    • 14.3.5 Spain
    • 14.3.6 Rest-of-Europe
  • 14.4 Asia-Pacific
    • 14.4.1 China
    • 14.4.2 Japan
    • 14.4.3 India
    • 14.4.4 South Korea
    • 14.4.5 Australia
    • 14.4.6 Singapore
    • 14.4.7 Rest-of-Asia-Pacific
  • 14.5 Latin America and Middle East
    • 14.5.1 Brazil
    • 14.5.2 Mexico
    • 14.5.3 Saudi Arabia
    • 14.5.4 Rest-of-Latin America and Middle East
  • 14.6 Rest-of-the-World

15 Company Profiles

  • 15.1 Company Overview
    • 15.1.1 Abcam plc
      • 15.1.1.1 Company Overview
      • 15.1.1.2 Role of Abcam plc in the Global EV-Based Liquid Biopsy Market
      • 15.1.1.3 Major Products: Key Specifications
      • 15.1.1.4 Key Competitors
      • 15.1.1.5 Analyst Perspective
    • 15.1.2 Bio-Techne Corporation
      • 15.1.2.1 Company Overview
      • 15.1.2.2 Role of Bio-Techne Corporation in the Global EV-Based Liquid Biopsy Market
      • 15.1.2.3 Major Products: Key Specifications
      • 15.1.2.4 Key Competitors
      • 15.1.2.5 Analyst Perspective
    • 15.1.3 Horiba Ltd.
      • 15.1.3.1 Company Overview
      • 15.1.3.2 Role of Horiba Ltd. in the Global EV-Based Liquid Biopsy Market
      • 15.1.3.3 Major Products: Key Specifications
      • 15.1.3.4 Key Competitors
      • 15.1.3.5 Analyst Perspective
    • 15.1.4 Qiagen N.V.
      • 15.1.4.1 Company Overview
      • 15.1.4.2 Role of Qiagen N.V. in the Global EV-Based Liquid Biopsy Market
      • 15.1.4.3 Major Products: Key Specifications
      • 15.1.4.4 Key Competitors
      • 15.1.4.5 Analyst Perspective
    • 15.1.5 Thermo Fisher Scientific, Inc.
      • 15.1.5.1 Company Overview
      • 15.1.5.2 Role of Thermo Fisher Scientific, Inc. in the Global EV-Based Liquid Biopsy Market
      • 15.1.5.3 Major Products: Key Specifications
      • 15.1.5.4 Key Competitors
      • 15.1.5.5 Analyst Perspective
    • 15.1.6 Malvern Panalytical Ltd
      • 15.1.6.1 Company Overview
      • 15.1.6.2 Role of Malvern Panalytical Ltd in the Global EV-Based Liquid Biopsy Market
      • 15.1.6.3 Major Products: Key Specifications
      • 15.1.6.4 Key Competitors
      • 15.1.6.5 Analyst Perspective
    • 15.1.7 Lonza Group AG
      • 15.1.7.1 Company Overview
      • 15.1.7.2 Role of Lonza Group AG in the Global EV-Based Liquid Biopsy Market
      • 15.1.7.3 Major Products: Key Specifications
      • 15.1.7.4 Key Competitors
      • 15.1.7.5 Analyst Perspective
    • 15.1.8 Revvity, Inc. (PerkinElmer, Inc.)
      • 15.1.8.1 Company Overview
      • 15.1.8.2 Role of Revvity, Inc. (PerkinElmer Inc.) in the Global EV-Based Liquid Biopsy Market
      • 15.1.8.3 Major Products: Key Specifications
      • 15.1.8.4 Key Competitors
      • 15.1.8.5 Analyst Perspective
    • 15.1.9 Takara Bio Inc.
      • 15.1.9.1 Company Overview
      • 15.1.9.2 Role of Takara Bio Inc. in the Global EV-Based Liquid Biopsy Market
      • 15.1.9.3 Major Products: Key Specifications
      • 15.1.9.4 Key Competitors
      • 15.1.9.5 Analyst Perspective
    • 15.1.10 Norgen Biotek Corp.
      • 15.1.10.1 Company Overview
      • 15.1.10.2 Role of Norgen Biotek Corp. in the Global EV-Based Liquid Biopsy Market
      • 15.1.10.3 Major Products: Key Specifications
      • 15.1.10.4 Key Competitors
      • 15.1.10.5 Analyst Perspective
    • 15.1.11 Emerging Companies
      • 15.1.11.1 Mursla Bio
      • 15.1.11.2 Nanostics Inc.
      • 15.1.11.3 Mercy BioAnalytics, Inc.
      • 15.1.11.4 Clara Diagnostics, Inc. (Clara Biotech)